AI-Personalized Radiation for High-Risk Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new way to plan prostate cancer treatment using artificial intelligence and advanced imaging. It’s for people with high-risk prostate cancer that hasn’t spread to lymph nodes or other parts of the body, and who have not had prior radiation to the prostate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a biopsy that confirms prostate cancer (if the biopsy is more than a year old, a new one may be needed).
- Your cancer should be high-risk or very high-risk according to standard guidelines (NCCN).
- You must have had a PSMA-PET/CT, MRI, or PSMA-PET/MR scan of your prostate.
- You cannot have had any prior radiation therapy to the prostate or pelvis.
- Your cancer must not have spread to lymph nodes in the pelvis or to distant parts of the body.
- Your PSA level must be 50 ng/mL or lower before starting any hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to customize your radiation therapy and hormone treatment for high-risk prostate cancer. It aims to improve treatment precision and reduce side effects.
This trial tests a new type of radiation therapy that is customized for each patient's prostate cancer. The radiation targets the tumor more precisely, which may help reduce side effects while treating the cancer effectively.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This trial tests whether using a special PSMA-PET scan to guide radiation therapy improves treatment for men with high-risk prostate cancer that hasn't spread. You would receive standard radiation plus hormone therapy, and the scan helps the doctor target the radiation more precisely.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.